OvaScience Inc. (NASDAQ:OVAS)’s share price was up 4.2% during trading on Monday . The company traded as high as $5.29 and last traded at $5.27, with a volume of 210,651 shares. The stock had previously closed at $5.06.

A number of equities analysts have commented on OVAS shares. Oppenheimer Holdings Inc. restated a “hold” rating on shares of OvaScience in a research note on Monday, April 25th. Credit Suisse Group AG restated a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. S&P Equity Research lowered their price objective on OvaScience from $10.82 to $8.83 in a research note on Monday, March 21st. Finally, Leerink Swann restated a “hold” rating and set a $7.00 price objective (up previously from $6.00) on shares of OvaScience in a research note on Sunday, May 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $12.37.

The stock’s 50-day moving average is $5.83 and its 200 day moving average is $7.42. The firm’s market cap is $144.29 million.

OvaScience (NASDAQ:OVAS) last announced its earnings results on Thursday, May 5th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.08. During the same quarter in the previous year, the firm earned ($0.65) EPS. The firm earned $0.15 million during the quarter, compared to analysts’ expectations of $0.14 million. The firm’s revenue was up 630.0% on a year-over-year basis. Equities research analysts expect that OvaScience Inc. will post ($3.14) earnings per share for the current year.

In other news, Director Richard Aldrich acquired 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average price of $7.64 per share, for a total transaction of $152,800.00. Following the completion of the purchase, the director now owns 604,185 shares in the company, valued at $4,615,973.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michelle Dipp acquired 425,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 1st. The stock was purchased at an average price of $7.00 per share, for a total transaction of $2,975,000.00. Following the purchase, the chief executive officer now owns 971,921 shares of the company’s stock, valued at approximately $6,803,447. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in OvaScience stock. AWM Investment Company Inc. boosted its stake in shares of OvaScience Inc. (NASDAQ:OVAS) by 1.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 116,352 shares of the company’s stock after buying an additional 1,352 shares during the period. AWM Investment Company Inc. owned approximately 0.43% of OvaScience worth $1,137,000 as of its most recent SEC filing.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.